Offering a variety of enhanced features for image optimization and improved workflow efficiencies, the Sierra NMUS1 device reportedly includes the first software specifically designed for neuromuscular ultrasound applications.
Providing an array of benefits to bolster image quality and workflow efficiencies, the newly launched Sierra NMUS1™ combines neuromuscular ultrasound imaging with electrodiagnostic testing capabilities.
Featuring software specifically tailored to neuromuscular ultrasound, the Sierra NMUS1 device (Cadwell Industries) enables clinicians to access improved image quality through edge enhancement, advanced speckle reduction and spatial compounding, according to the company.
Cadwell Industries said the Sierra NMUS1 device offers three probes, a C-5-2 Curvilinear Probe, an L14-4 Linear Probe, and an HL18-4 Linear Hockey Stick Probe, that facilitate needle visualization and enhanced image quality. The neuromuscular ultrasound device also includes upgraded Sierra® 4 software with advanced artifact reduction and trace resolution, according to Cadwell Industries.
Through the Sierra 4 software, the Sierra NMUS1 device integrates electromyography (EMG) and nerve conduction studies (NCS). Other efficiencies of the Sierra NMUS1 system include automated labeling of images and results, easy measurement and annotation of images; and report generation that allows clinicians to document electrodiagnostic and imaging findings in one report, according to Cadwell Industries.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.